1. Introduction
As of July 1st, there had been 249,659 SARS-CoV-2 infections diagnosed in Spain, causing at least 28,363 deaths during the same period [1], and no effective therapy available. During the first wave of the SARS-CoV-2 pandemic, the use of corticosteroids for the treatment of COVID-19 was controversial, based on data from influenza pneumonia and SARS-CoV-1 infection [2]. However, they were used in many cases, due to the lack of effective therapy for this entity. There was not enough knowledge about the different phases of the illness nor had there been time to generate scientific evidence on the safety and effectiveness of different potential treatments [3].
Initially, drugs with presumed antiviral properties, such as hydroxychloroquine or lopinavir/ritonavir, were widely administered, but failed to demonstrate benefits [4]. Progressively, it became clear that elevation of inflammatory biomarkers and certain clinical features such as fever, pointed towards a hyper-inflammatory state. Based on this rationale, despite controversies, and in the absence of a better option, steroid treatment was considered to treat patients with COVID19 in many cases.
The first studies that analyzed the role of steroid treatment in COVID-19 did not support their use, in some cases for fear of delayed viral clearance based on the previous scarce evidence with SARS and MERS [5,6]. However, when viral clearance of SARS-CoV-2 was analyzed in patients who received corticosteroid treatment, there was no evidence of delayed viral clearance [7,8]. Furthermore, other single center studies suggested a positive impact of corticosteroids in mortality of patients with COVID-19 who needed supplementary oxygen [9,10].
The results of the RECOVERY trial [11] suggest that treatment with dexamethasone is beneficial for patients with COVID-19 that present with hypoxemia, which motivated the change in the World Health Organization recommendations [12]. In the present study, we analyze real-world data with the aim of confirming the consistency of these findings in a large Spanish multicenter cohort.
2. Material/Patients and Methods
2.1. Setting and Study Design
The present observational study is based on the SEMI (Spanish Society of Internal Medicine)-COVID-19 Registry. This is an ongoing, nationwide multicenter anonymized online database of consecutive adult patients admitted with SARS-CoV-2 laboratory-confirmed pneumonia from 131 different Spanish hospitals.
As described elsewhere [13], inclusion criteria for the registry were age ≥ 18 years and first hospital discharge with a confirmed diagnosis of COVID-19. Exclusion criteria were subsequent admissions of the same patient and denial or withdrawal of informed consent. Patients were cared for at their attending physician’s discretion, according to local protocols and clinical judgment.
A retrospective cohort study was designed to compare the differences in all-cause mortality between patients who received corticosteroids as part of the treatment for COVID-19 (independently of the dose, duration of the treatment and moment of initiation) and those who did not.
2.2. Data Collection
The registry includes epidemiological, clinical, laboratory and radiologic data extracted from electronic medical records. More in-depth information on the registry is available in previously published works [13].
2.3. Definitions
We considered SARS-CoV-2 infected patients those with a microbiological confirmation by reverse transcription polymerase chain reaction (RT-PCR) testing of a respiratory sample. Exposure to corticosteroids was defined as the use of systemic corticosteroids at any time during the hospital admission. Different types of corticosteroids were considered (dexamethasone, methylprednisolone, prednisone). The effect of different doses or different corticosteroids is analyzed elsewhere (Lavilla-Olleros C. et al. in press).
The main outcome variable was in-hospital mortality.
The diagnosis and grading of ARDS was determined according to modified Berlin criteria [14] (in non-ventilated patients, the PEEP value in the modified criteria was not taken into consideration): mild: PaO2/FiO2 200–300 mmHg (PEEP or CPAP ≥ 5 cmH2O, or non-ventilated); moderate: PaO2/FiO2 100–200 (PEEP ≥ 5 cmH2O, or non-ventilated); severe: PaO2/FiO2 ≤ 100 mmHg (PEEP ≥ 5 cmH2O, or non-ventilated).
2.4. Statistical Analysis
Quantitative variables were expressed as means and standard deviations (SD) and/or medians and interquartile ranges, and qualitative variables as frequencies and percentages. The association of baseline characteristics among the steroid and control cohorts with mortality was assessed through univariable conditional logistic regression to compute crude odds ratios (ORs) and their 95% confidence intervals (CIs).
To compare differences between survivors and non-survivors, the Mann–Whitney U test, X2 test, Fisher’s exact test or Student t test were used where appropriate. To explore risk factors associated with in-hospital death, univariable analysis and multivariable logistic regression models were used. Variables with a p < 0.05 in univariable analysis were selected into the multivariable.
To reduce the effect of corticosteroid treatment selection bias and potential confounding, we adjusted for differences in baseline characteristics by a propensity score, which predicts the patient’s probability of being treated with corticosteroids regardless of confounding factors, using multivariable logistic regression. Potential confounders considered in propensity score matching analysis were those variables included in the final model by means of stepwise backward elimination procedures. The effect of steroid treatment on clinical outcome was analyzed by a multivariable logistic regression, adjusted for major variables associated with mortality; the individual propensity score was incorporated into the model as a covariate, to calculate the propensity adjusted odds ratio (OR), as described elsewhere [10].
All statistical analyses were performed using SPSS system (version 26.0 for Windows, SPSS Inc., Chicago, IL, USA). The statistical significance level was set at a two-sided p value of <0.05. An odds ratio (OR) was reported along with 95% confidence interval (CI).
3. Results
As of July 2020, 14,921 patients were included in the SEMI-COVID-19 Registry. Among them, 5262 (35.26%) patients were treated with corticosteroids and 9659 (64.73%) patients were not (from now on, control cohort). Median time to corticosteroid treatment from symptoms onset was 10 days (IQR 7 to 14 days).
3.1. Clinical Characteristics
The clinical characteristics of the steroid and control cohorts are shown in Table 1. There were significant differences between the group of patients who received steroid treatment and those who did not in all the baseline characteristics and laboratory findings considered relevant (including known poor prognosis risk factors such as hypertension, obesity, diabetes, D-dimer or C-RP which were more prevalent or presented higher levels among those who received steroids), except for the total lymphocyte count, which showed no significant differences.
3.2. In-Hospital Mortality of Patients Treated with Corticosteroids Compared to Patients Not Treated with Corticosteroids
Overall, in-hospital mortality was 20.5%. Characteristics of survivors and non-survivors are shown in Table 2.
Notably, whereas in the univariable analysis, in-hospital mortality was higher in patients treated with corticosteroids than in controls (16.2% versus 28.5%; OR 2.068 (95% confidence interval, 1.908 to 2.242); p = 0.0001), when adjusting by occurrence of established ARDS (all severities included), mortality was significantly lower in the steroid treatment group (43.4% versus 57.6%; OR 0.564 (95% confidence interval, 0.503 to 0.633); p = 0.0001). Furthermore, we could see a greater benefit of steroid treatment in mortality as the severity of the lung damage increased (6% vs. 10.1% in mild ARDS, 26% vs. 51.2% in moderate ARDS, and 66.6% vs. 84.3% in severe ARDS). Mortality was higher in the subgroup of patients without ARDS who received steroid treatment (5% vs. 9.9%).
Age-adjusted Charlson comorbidity index (OR 1.481 (1.440–1.524), p = 0.000), low SpO2/FiO2 ratio at admission (OR 0.997 (0.996–0.998), p = 0.000), established ARDS at any point during the course of the disease 4.233 (3.958 to 4.527), p = 0.000), high values of LDH (OR 1.001 (1.000–1.001), p = 0.000) and high values of C-reactive protein (OR 1.002 (1.001 to 1.003), p = 0.000) were independent risk factors for mortality, whereas steroid treatment (OR 0.793 (0.7682–0.923), p = 0.003), Tocilizumab treatment (OR 0.458 (0.371 to 0.564), p = 0.001), Hydroxychloroquine treatment (OR 0.342( 0.281 to 0.416), p = 0.000) and Lopinavir/Ritonavir treatment (OR 0.620 (0.533 to 0.723), p = 0.000) were independent protective factors.
A propensity score for steroid treatment was developed to adjust for differences in baseline characteristics. The propensity score for steroid treatment included the following variables: hypertension, age-adjusted Charlson comorbidity index, diabetes, onco-hematologic underlying disease, acute coronary syndrome, COPD, obesity, moderate-severe chronic kidney disease, SpO2/FiO2, lymphocyte, LDH and C-RP at admission. The propensity-score-matched cohort is displayed in Table 1.
Table 3 shows the risk factors for mortality in both univariable and multivariable analyses, including those adjusted by the propensity score for steroid treatment. When adjusting these results including the propensity score as a covariate, the overall in-hospital mortality remained significantly lower in the steroid treatment group (OR 0.774 (0.660 to 0.907), p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24).
4. Discussion
In the present study, we observed that patients with SARS-COV-2 pneumonia with established acute respiratory distress syndrome who received corticosteroids as part of their treatment had 24% inferior in-hospital mortality than those who did not.
Although retrospective studies on steroid effect on COVID-19 mortality are discordant, our results are consistent with those reported in the RECOVERY trial. Other retrospective studies support these results [9,10].
Interestingly, as reported in the RECOVERY trial, steroid treatment did not show a beneficial effect on patients who did not require oxygen, on the contrary, mortality in this subset was higher than in the non-steroid treatment group [11]. This can be at least partly explained by the characteristics of the patients who received steroids, who presented a higher prevalence of dismal prognostic factors such as hypertension, obesity or diabetes among others and higher levels of biomarkers associated with poor outcome in COVID-19 (D-dimer, C-RP). Nevertheless, we cannot exclude that in some cases steroid could have been administered too early, during the viral phase of the disease, which has been associated with worse outcomes [15,16]. In addition, corticosteroids are not exempt of adverse effects, in particular when given at high-dose, and in patients without severe involvement the risk-benefit ratio may not be favorable.
Furthermore, our results suggest that the greater the respiratory failure, the larger the impact on mortality of the steroid treatment. These results are in accordance with the physiopathology of ARDS in COVID-19 which is based in the exuberant inflammatory response in the lungs [17].
The only corticosteroid tested in the RECOVERY trial was dexamethasone, at 6 mg per day [11]. In the present study, different corticosteroids at different dosage regimens were used. This real-life use of diverse corticosteroids in COVID-19 was associated with a decrease in mortality in patients with COVID-19 that fulfilled ARDS criteria. Dexamethasone doses in the RECOVERY trial are equivalent to medium prednisone doses. It is a matter of controversy whether higher doses or even pulses would present better results in COVID-19 (Lavilla-Olleros C et al. in press) [18]. However, some authors believe that viral clearance could be affected by high dose corticosteroids, but not by low-dose [19]; consequently, this must be taken into consideration when analyzing different doses of steroid treatment for COVID-19.
The major strength of the present study was the great number of patients included, and being a multicenter registry with a highly heterogeneous population (as there were no exclusion criteria), which we believe provides real-life results, generalizable to other populations.
Limitations of the present study are those typical of retrospective studies, including the occasional missing data. Unfortunately, the precise moment of developing ARDS criteria relative to symptoms onset or corticosteroid administration was not appropriately registered, as was neither the exact corticosteroid used in each case, limiting the subgroup analysis. To overcome selection bias, we developed a propensity score for steroid treatment from the baseline characteristics of patients, and performed an adjusted analysis.
Our real-life results support evidence from clinical trials in favor of the use of steroid treatment in patients with SARS-COV-2 pneumonia and established ARDS. The ideal dosage and the optimal moment in the course of the disease require further investigation. Future studies should address as well whether steroid treatment has a class effect in COVID-19 or is specific for some drugs, and determine if synergies with other anti-inflammatory or antiviral drugs exist.
Conceptualization, A.F.-C., J.A.V., J.M.R.-R. and R.G.-H.; data curation, A.M.-G., C.L.-O., V.G.-G., P.W., A.D.B.-E., M.R.-R., J.L., D.F.-B., V.A.B., A.P.A.d.L., M.d.l.R.P.-P., J.N.A.-P., A.L.-I.R., A.H.-M., M.G.d.M., B.A., C.M.-P., M.d.l.S.N.-A., J.F.S.-D., R.M.G.-M., C.S.-G. and H.M.-M.; formal analysis, A.M.-G., A.F.-C. and C.A.-G.; methodology, A.F.-C.; project administration, J.A.V., J.M.R.-R. and R.G.-H.; supervision, A.F.-C.; writing—original draft, A.M.-G.; writing—review and editing, A.F.-C., C.L-O., V.G.-G., C.A.-G., P.W., A.D.B.-E., J.A.V., M.R.-R., J.L., D.F.-B., V.A.B., A.P.A.d.L., M.d.l.R.P.-P., J.N.A.-P., A.L.-I.R., A.H.-M., M.G.d.M., B.A., C.M.-P., M.d.l.S.N.-A., J.F.S.-D., R.M.G.-M., C.S.-G., H.M.-M., J.M.R.-R. and R.G.-H. All authors have read and agreed to the published version of the manuscript.
There was no funding granted for this article.
This study conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Research Ethics Committee of Málaga on 27 March 2020 (Ethics Committee code: SEMI-COVID-19 27-03-20), as per the guidelines of the Spanish Agency of Medicines and Medical Products.
Only patients who had previously given consent for their medical records to be used for medical research were included in this registry. Data confidentiality and patient anonymity were always maintained, in accordance with Spanish regulations on observational studies.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
We gratefully acknowledge all the investigators who participate in the SEMI-COVID-19 registry. This study was presented at the “31st ECCMID 2021” as a ePoster (Session name: 12e. Drug development and treatment modalities (incl. clinical trials).
The authors declare they no conflicts of interest related to this article.
SARS-CoV-2: severe acute respiratory syndrome Coronavirus -2; COVID-19: coronavirus disease 2019; corticosteroids: glucocorticoids or corticoids; OR: odds ratio; PaO2/FiO2: arterial oxygen tension/inspiratory oxygen fraction; SpO2/FiO2: plasma oxygen saturation/inspiratory oxygen fraction; ARDS: acute respiratory distress syndrome; CRP: C-reactive protein; PEEP: positive end expiratory pressure; SD: standard deviation; CI: confidence interval; RRR: relative risk reduction; IQR: interquartile range; LDH: lactate dehydrogenase; SpO2: plasma oxygen saturation; ICU: intensive care unit.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Baseline characteristics of patients in the steroid and non-steroid complete cohort and in the propensity-matched cohort.
| Complete Cohort | Propensity Score Matched Cohort | |||||
|---|---|---|---|---|---|---|
| Non-Steroid Treatment | Steroid Treatment | p Value | Non-Steroid Treatment | Steroid Treatment | p Value | |
| Baseline Characteristics and Underlying Medical Conditions | ||||||
| Sex (Men, %) | 5208 (54.0%) | 3323 (63.2%) | 0.000 | 1269 (55.1%) | 1011 (65.4%) | 0.000 |
| Age (mean, SD) | 65 | 70 | 0.000 | 67.8 | 70.5 | 0.000 |
| Age-adjusted Charlson comorbidity index (mean) | 3.4 | 4.0 | 0.000 | 3.7 | 4.2 | 0.000 |
| High blood pressure | 4590 (47.6%) | 2983 (56.8%) | 0.000 | 1242 (53.9%) | 953 (61.5%) | 0.000 |
| Diabetes | 1724 (17.9%) | 1140 (21.7%) | 0.000 | 471 (20.4%) | 370 (23.9%) | 0.011 |
| Acute coronary syndrome | 703 (7.3%) | 485 (9.2%) | 0.000 | 193 (8.4%) | 162 (10.5%) | 0.028 |
| Moderate to severe chronic kidney disease | 516 (5.4%) | 388 (7.4%) | 0.000 | 154 (6.7%) | 123 (7.9%) | 0.137 |
| Dyslipidemia | 3630 (37.7%) | 2272 (43.3%) | 0.000 | 964 (41.8%) | 711 (45.9%) | 0.012 |
| COPD | 505 (5.2%) | 516 (9.8%) | 0.000 | 170 (7.4%) | 199 (12.8%) | 0.000 |
| Stroke | 664 (6.9%) | 417 (7.9%) | 0.019 | 68 (3.0%) | 43 (2.8%) | 0.750 |
| Obesity | 1657 (18.8%) | 1209 (25.3%) | 0.000 | 543 (23.5%) | 464 (30.0%) | 0.000 |
| Leukemia | 93 (1.0%) | 86 (1.6%) | 0.000 | 24 (1.0%) | 24 (1.5%) | 0.163 |
| Lymphoma | 120 (1.2%) | 92 (1.7) | 0.013 | 32 (1.4%) | 27 (1.7%) | 0.378 |
| Hematologic disease | 211 (2.2%) | 175 (3.3%) | 0.000 | 55 (2.4%) | 50 (3.2%) | 0.116 |
| Solid tumor with metastases | 218 (2.3%) | 105 (2.0%) | 0.291 | 60 (2.6%) | 34 (2.2%) | 0.421 |
| Solid tumor without metastases | 581 (6.0%) | 351 (6.6%) | 0.119 | 150 (6.5%) | 104 (6.7%) | 0.797 |
| Malignancy | 787 (8.2%) | 454 (8.6%) | 0.323 | 208 (9%) | 137 (8.8%) | 0.848 |
| Moderate to severe liver disease | 90 (0.9%) | 58 (1.1%) | 0.315 | 24 (1%) | 21 (1.4%) | 0.372 |
| Laboratory findings at admission | ||||||
| Urea (mg/dL) | 45.5 | 53.4 | 0.000 | 49.1 | 55.7 | 0.000 |
| LDH (U/L) | 354 | 403 | 0.000 | 385.58 | 437.4 | 0.000 |
| C-reactive protein (mg/L) | 52.1 | 70.5 | 0.000 | 94.1 | 130.9 | 0.000 |
| Lymphocytes (per 106/L) | 1437.3 | 1169.4 | 0.000 | 1150.6 | 1047.4 | 0.090 |
| D-Dimer (ng/mL) | 1607.3 | 2430.9 | 0.000 | 1881.8 | 2563.4 | 0.076 |
| Interleukin-6 (pg/mL) | 47.06 | 95.7 | 0.000 | 53.8 | 103.5 | 0.003 |
| Ferritin (mcg/L) | 750.5 | 1209.2 | 0.000 | 801.4 | 1281.4 | 0.000 |
| Respiratory parameters | ||||||
| SpO2/FiO2 at admission | 273.0 | 203.8 | 0.000 | 405.4 | 375.6 | 0.000 |
| ARDS | 1082 (11.2%) | 1549 (29.6%) | 0.000 | 597 (26.0%) | 928 (60.1%) | 0.000 |
Baseline characteristics of patients in the survivor and non-survivor cohort.
| Survivors (n = 11,862) | Non—Survivors (n = 3059) | p Value | |
|---|---|---|---|
| Baseline Characteristics and Underlying Medical Conditions | |||
| Sex (Men, %) | 6619 (55.9%) | 1912 (62.6%) | 0.000 |
| Age (mean, SD) | 64.18 (15.9%) | 79.67 (10.6%) | 0.000 |
| Age-adjusted Charlson comorbidity index (mean) | 3.08 (2.5%) | 5.70 (2.41%) | 0.000 |
| High blood pressure | 5423 (45.8%) | 2150 (70.4%) | 0.000 |
| Diabetes | 1993 (16.9%) | 871 (28.6%) | 0.000 |
| Ischemic heart disease | 751 (6.3%) | 437 (14.3%) | 0.000 |
| Moderate to severe chronic kidney disease | 517 (4.4%) | 387 (12.7%) | 0.000 |
| Dyslipidemia | 4360 (36.8%) | 1542 (50.6%) | 0.000 |
| COPD | 645 (5.4%) | 376 (12.3%) | 0.000 |
| CVA | 657 (5.6%) | 424 (13.9%) | 0.000 |
| Obesity | 2253 (20.7%) | 613 (21.4%) | 0.045 |
| Onco-hematologic | 1050 (8.9%) | 524 (17.2%) | 0.000 |
| Hematologic disease | 231 (2%) | 155 (5.1%) | 0.000 |
| Leukemia | 106 (0.9%) | 73 (2.4%) | 0.000 |
| Lymphoma | 126 (1.1%) | 86 (2.8%) | 0.000 |
| Solid tumor with metastases | 226 (1.9%) | 97 (3.2%) | 0.000 |
| Solid tumor without metastases | 633 (5.3%) | 299 (9.8%) | 0.000 |
| Moderate to severe liver disease | 105 (0.9%) | 43 (1.4%) | 0.009 |
| Laboratory findings at admission | |||
| Urea (mg/dL) | 41.65 (29.7) | 74.46 (51.35) | 0.000 |
| Lactate dehydrogenase (U/L) | 347.06 (193.9) | 476.80 (299.77) | 0.000 |
| C-reactive protein (mg/L) | 77.04 (81.5) | 127.24 (104.14) | 0.000 |
| Lymphocyte count (per 106/L) | 1174.68 (1773.5) | 1139.90 (3317.10) | 0.578 |
| D-Dimer (ng/mL) | 1623.3 | 6074.50 | 0.000 |
| Interleukin-6 (pg/mL) | 60.50 (173.8) | 126.45 (183.48) | 0.000 |
| Ferritin (mcg/L) | 892.35 (1039.4) | 1235.03 (1375.82) | 0.000 |
| Respiratory parameters | |||
| SatO2/FiO2 (SD) | 423.73 (63.6) | 356.01 (106.1) | 0.000 |
| ARDS | 2483 (21.0%) | 2413 (79.8%) | 0.00 |
| Treatments received | |||
| Steroid treatment | 3763 (31.7%) | 1499 (49.0%) | 0.000 |
| Hydroxychloroquine | 10,487 (88.5%) | 2285 (74.7%) | 0.000 |
| Lopinavir/Ritonavir | 7549 (63.7%) | 1599 (52.4%) | 0.000 |
| Interferon | 1125 (9.5%) | 536 (17.6%) | 0.000 |
| Tocilizumab | 948 (8.0%) | 309 (10.1%) | 0.000 |
| Anakinra | 64 (0.5%) | 26 (0.9%) | 0.046 |
Risk factors for mortality in both univariable and multivariable analyses (including a multivariable analysis including the propensity score for steroid treatment as a covariate).
| Univariable Analysis | Multivariable Analysis | Multivariable Adjusted with Propensity Score | ||||
|---|---|---|---|---|---|---|
| N = 14.921 | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value |
| Basal characteristics and underlying medical conditions | ||||||
| Sex (Women) | 0.756 (0.697–0.821) | 0.000 | ||||
| Age | 1.088 (1.084–1.092) | 0.000 | ||||
| Age-adjusted Charlson comorbidity index | 1.445 (1.420–1.470) | 0.000 | 1.481 (1.440–1.524) | 0.000 | 1.440 (1.397–1.485) | 0.000 |
| High blood pressure | 2.824 (2.592–3.076) | 0.000 | ||||
| Diabetes | 1.972 (1.799–2.163) | 0.000 | ||||
| Ischemic heart disease | 2.470 (2.179–2.800) | 0.000 | ||||
| Moderate to severe chronic kidney disease | 3.184 (2.772–3.656) | 0.000 | ||||
| Dyslipidemia | 1758 (1.623–1.905) | 0.000 | ||||
| COPD | 2.441 (2.135–2.791) | 0.000 | ||||
| Ictus | 2.754 (2.420–3.315) | 0.000 | ||||
| Obesity | 1.133 (1.024–1.254) | 0.016 | ||||
| Onco-hematologic | 2.128 (1.900–2.384) | 0.000 | ||||
| Hematologic disease | 2.687 (2.183–3.306) | 0.000 | ||||
| Leukemia | 2.713 (2.008–3.665) | 0.000 | ||||
| Lymphoma | 2.693 (2.042–3.553) | 0.000 | ||||
| Solid tumor with metastases | 1.688 (1.326–2.148) | 0.000 | ||||
| Solid tumor without metastases | 1.922 (1.664–2.219) | 0.000 | ||||
| Moderate to severe liver disease | 1.596 (1.117–2.282) | 0.010 | ||||
| Laboratory findings at admission | ||||||
| Urea (mg/dL) | 1.022 (1.021–1.023) | 0.000 | ||||
| LDH (U/L) | 1.003 (1.0020–1.003) | 0.000 | 1.001 (1.000–1.001) | 0.000 | 1.000 (1.000–1.001) | 0.005 |
| C-reactive protein (mg/L) | 1.006 (1.005–1.006) | 0.000 | 1.002 (1.001–1.003) | 0.000 | 1.000 (0.999–1.002) | 0.526 |
| Lymphocytes (per 106/L) | 1.00 (1.00–1.00) | 0.436 | ||||
| D-Dimer (ng/mL) | 1.00 (1.00–1.00) | 0.000 | ||||
| Interleukin-6 (pg/mL) | 1.001 (1.001–1.002) | 0.000 | ||||
| Ferritin (mcg/L) | 1.000 (1.000–1.000) | 0.000 | ||||
| Respiratory parameters | ||||||
| SatO2/FiO2 (SD) | 0.991 (0.991–0.992) | 0.000 | 0.997 (0.996–0.998) | 0.000 | 0.998 (0.997–0.999) | 0.000 |
| ARDS | 14.845 (13.444–16.393) | 0.000 | 4.233 (3.958–4.527) | 0.000 | 4.299 (3.393–4.540) | 0.000 |
| Treatments administered | ||||||
| Steroid treatment | 2.068 (1.908–2.242) | 0.000 | 0.793 (0.682–0.923) | 0.003 | 0.774 (0.660–0.907) | 0.002 |
| Hydroxychloroquine | 0.386 (0.349–0.426) | 0.000 | 0.342 (0.281–0.416) | 0.000 | ||
| Lopinavir/Ritonavir | 0.626 (0.578–0.679) | 0.000 | 0.620 (0.533–0.723) | 0.000 | 0.636 (0.542–0.747) | 0.000 |
| Interferon | 2.031 (1.816–2.271) | 0.000 | ||||
| Tocilizumab | 1.294 (1.130–1.481) | 0.000 | 0.458 (0.371–0.564) | 0.001 | 0.476 (0.383–0.592) | 0.000 |
| Anakinra | 1.587 (1.004–2.507) | 0.048 | ||||
Supplementary Materials
The following are available online at
References
1. COVID-19: Casos Confirmados, Muertes y Recuperados Por día en España 2021. Available online: https://es.statista.com/estadisticas/1107506/covid-19-casos-confirmados-muertes-y-recuperados-por-dia-espana/ (accessed on 1 October 2021).
2. Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet; 2020; 395, pp. 473-475. [DOI: https://dx.doi.org/10.1016/S0140-6736(20)30317-2]
3. Dagens, A.; Sigfrid, L.; Cai, E.; Lipworth, S.; Cheung, V.; Harris, E.; Bannister, P.; Rigby, I.; Horby, P. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: Rapid review. BMJ; 2020; 369, m1936. [DOI: https://dx.doi.org/10.1136/bmj.m1936] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32457027]
4. WHO Pan, H.; Peto, R.; Henao-Restrepo, A.M.; Preziosi, M.P.; Sathiyamoorthy, V.; Abdool Karim, Q.; Alejandria, M.M.; Hernandez Garcia, C.; Kieny, M.P. et al. Solidarity Trial Consortium repurposed antiviral drugs for COVID-19—Interim WHO solidarity trial results. N. Engl. J. Med.; 2021; 384, pp. 497-511. [DOI: https://dx.doi.org/10.1056/nejmoa2023184]
5. Arabi, Y.M.; Mandourah, Y.; Al-Hameed, F.; Sindi, A.A.; Almekhlafi, G.; Hussein, M.A.; Jose, J.; Pinto, R.; Al-Omari, A.; Kharaba, A. et al. Corticosteroid therapy for critically Ill patients with Middle East respiratory syndrome. Am. J. Respir. Crit. Care Med.; 2018; 197, pp. 757-767. [DOI: https://dx.doi.org/10.1164/rccm.201706-1172OC] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29161116]
6. Lee, N.; Chan, K.A.; Hui, D.; Ng, E.K.; Wu, A.; Chiu, R.W.; Wong, V.W.; Chan, P.; Wong, K.; Wong, E. et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J. Clin. Virol.; 2004; 31, pp. 304-309. [DOI: https://dx.doi.org/10.1016/j.jcv.2004.07.006] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15494274]
7. Fang, X.; Mei, Q.; Yang, T.; Li, L.; Wang, Y.; Tong, F.; Geng, S.; Pan, A. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J. Infect.; 2020; 81, pp. 147-178. [DOI: https://dx.doi.org/10.1016/j.jinf.2020.03.039] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32283153]
8. Zha, L.; Li, S.; Pan, L.; Tefsen, B.; Li, Y.; French, N.; Chen, L.; Yang, G.; Villanueva, E.V. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust.; 2020; 212, pp. 416-420. [DOI: https://dx.doi.org/10.5694/mja2.50577] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32266987]
9. Fadel, R.; Morrison, A.R.; Vahia, A.; Smith, Z.R.; Chaudhry, Z.; Bhargava, P.; Miller, J.; Kenney, R.M.; Alangaden, G.; Ramesh, M.S. et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin. Infect. Dis.; 2020; 71, pp. 2114-2120. [DOI: https://dx.doi.org/10.1093/cid/ciaa601] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32427279]
10. Fernandez-Cruz, A.; Ruiz-Antoran, B.; Munoz-Gomez, A.; Sancho-Lopez, A.; Mills-Sanchez, P.; Centeno-Soto, G.A.; Blanco-Alonso, S.; Javaloyes-Garachana, L.; Galan-Gomez, A.; Valencia-Alijo, A. et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-COV-2 infection mortality. Antimicrob. Agents Chemother.; 2020; 64, [DOI: https://dx.doi.org/10.1128/AAC.01168-20] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32571831]
11. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med.; 2021; 384, pp. 693-704. [DOI: https://dx.doi.org/10.1056/NEJMoa2021436] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32678530]
12. Rochwerg, B.; Agarwal, A.; Siemieniuk, R.A.; Agoritsas, T.; Lamontagne, F.; Askie, L.; Lytvyn, L.; Leo, Y.-S.; Macdonald, H.; Zeng, L. et al. A living WHO guideline on drugs for covid-19. BMJ; 2020; 370, m3379. [DOI: https://dx.doi.org/10.1136/bmj.m3379] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32887691]
13. Casas-Rojo, J.; Antón-Santos, J.; Millán-Núñez-Cortés, J.; Lumbreras, C.; Rincón, J.M.R.; Roy-Vallejo, E.; Artero-Mora, A.; Arnalich-Fernández, F.; García-Bruñén, J.; Vargas-Núñez, J. et al. Características clínicas de los pacientes hospitalizados con COVID-19 en España: Resultados del Registro SEMI-COVID-19. Rev. Clín. Esp.; 2020; 220, pp. 480-494. [DOI: https://dx.doi.org/10.1016/j.rce.2020.07.003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33994573]
14. Force, A.D.T.; Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. Acute respiratory distress syndrome: The Berlin Definition. JAMA; 2012; 307, pp. 2526-2533. [DOI: https://dx.doi.org/10.1001/jama.2012.5669]
15. Shionoya, Y.; Taniguchi, T.; Kasai, H.; Sakuma, N.; Imai, S.; Shikano, K.; Takayanagi, S.; Yahaba, M.; Nakada, T.-A.; Igari, H. et al. Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study. PLoS ONE; 2021; 16, e0256977. [DOI: https://dx.doi.org/10.1371/journal.pone.0256977] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34473766]
16. Fernández-Cruz, A.; Ruiz-Antorán, B.; Múñez-Rubio, E.; Sancho-López, A.; Callejas-Díaz, A.; Avendaño-Solá, C.; Ramos-Martinez, A. The right time for steroids in COVID-19. Clin. Infect. Dis.; 2021; 72, pp. 1486-1487. [DOI: https://dx.doi.org/10.1093/cid/ciaa865] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32585016]
17. Osuchowski, M.F.; Winkler, M.S.; Skirecki, T.; Cajander, S.; Shankar-Hari, M.; Lachmann, G.; Monneret, G.; Venet, F.; Bauer, M.; Brunkhorst, F.M. et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir. Med.; 2021; 9, pp. 622-642. [DOI: https://dx.doi.org/10.1016/S2213-2600(21)00218-6]
18. Ruiz-Irastorza, G.; Pijoan, J.-I.; Bereciartua, E.; Dunder, S.; Dominguez, J.; Garcia-Escudero, P.; Rodrigo, A.; Gomez-Carballo, C.; Varona, J.; Guio, L. et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. PLoS ONE; 2020; 15, e0239401. [DOI: https://dx.doi.org/10.1371/journal.pone.0239401] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32960899]
19. Li, S.; Hu, Z.; Song, X. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19. Clin. Infect. Dis.; 2020; 72, pp. 1297-1298. [DOI: https://dx.doi.org/10.1093/cid/ciaa829] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32588877]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2 laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids were compared to patients not treated with corticosteroids; and adjusted using a propensity-score for steroid treatment. From March–July 2020, 5.262 (35.26%) were treated with corticosteroids and 9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908 to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633]; p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of the steroid treatment. When adjusting these results including the propensity score as a covariate, in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907], p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24). These results support the use of glucocorticoids in COVID-19 in this subgroup of patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Fernández-Cruz, Ana 2
; Lavilla-Olleros, Cristina 3 ; Giner-Galvañ, Vicente 4 ; Ausín-García, Cristina 3 ; Wikman, Philip 4
; Bendala-Estrada, Alejandro D 3 ; Vargas, Juan A 5
; Rubio-Rivas, Manuel 6
; Laureiro, Jaime 7 ; Fernández-Bermúdez, Daniel 8 ; Buonaiuto, Verónica A 9 ; Antonio P Arenas de Larriva 10 ; María de los Reyes Pascual-Pérez 11
; Alcalá-Pedrajas, José N 12 ; Ane Labirua-Iturburu Ruiz 13 ; Hernández-Milián, Almudena 14 ; Marta Gómez del Mazo 15 ; Antequera, Beatriz 16 ; Mella-Pérez, Carmen 17
; María de la Sierra Navas-Alcántara 18 ; Soto-Delgado, Juan F 19 ; Gámez-Mancera, Rosa M 20 ; Sardiña-González, Cristina 21 ; Meijide-Míguez, Héctor 22 ; Ramos-Rincón, José M 23
; Gómez-Huelgas, Ricardo 9
; Bordon, Jose1 Internal Medicine Department, Hospital de Parla, 28981 Madrid, Spain;
2 Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro—Segovia de Arana, 28222 Madrid, Spain
3 Internal Medicine Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain;
4 Internal Medicine Department, Hospital Clínico Universitario de Sant Joan d’Alacant, Fundación para el Fomento de la Investigación Sanitaria y Biomédica en la Comunidad Valenciana (FISABIO), 03550 Alicante, Spain;
5 Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro—Segovia de Arana, 28222 Madrid, Spain;
6 Department of Internal Medicine, Bellvitge University Hospital, L’Hospitalet de Llobregat, 08907 Barcelona, Spain;
7 Doce de Octubre University Hospital, 28041 Madrid, Spain;
8 Internal Medicine Department, Costa del Sol Hospital, 29603 Marbella, Spain;
9 Internal Medicine Department, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA), 29010 Málaga, Spain;
10 Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Av. Menendez Pidal s/n, 14004 Córdoba, Spain;
11 Internal Medicine Department, University General Hospital of Elda, 03600 Alicante, Spain;
12 Internal Medicine Department, Pozoblanco Regional Hospital, 14400 Córdoba, Spain;
13 Santa Marina Hospital, 48004 Bilbao, Spain;
14 Internal Medicine Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain;
15 Internal Medicine Department, San Pedro Hospital, 26006 Logroño, Spain;
16 Internal Medicine Department, Sagunto Hospital, 46520 Valencia, Spain;
17 Universitary Hospital Complex of Ferrol, 15405 A Coruña, Spain;
18 Internal Medicine Department, Infanta Margarita Hospital, Cabra, 14940 Córdoba, Spain;
19 Internal Medicine Department, University Hospital of Salamanca, 37007 Salamanca, Spain;
20 Internal Medicine Department, University Hospital Virgen del Rocío, 41013 Sevilla, Spain;
21 Internal Medicine Department, Monforte de Lemos Public Hospital, 27400 Lugo, Spain;
22 Internal Medicine Department, Quironsalud Hospital, 15009 A Coruña, Spain;
23 Department of Clinical Medicine, Miguel Hernandez University of Elche, 03203 Alicante, Spain;